NCT01794793 / 2013-000267-84: Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies |
|
|
| Completed | 4 | 337 | Europe, Canada, Japan, US, RoW | Pasireotide, SOM230; Signifor, Cabergoline, dostinex, Pasireotide LAR | RECORDATI GROUP | Cushing's Disease, Acromegaly, Neuroendocrine Tumors, Pituitary Tumors, Ectopic ACTH Secreting (EAS) Tumors, Dumping Syndrome, Prostate Cancer, Melanoma Negative for bRAF, Melanoma Negative for nRAS | 07/23 | 07/23 | | |
